Autologous, gene-modified TCR-engineered T cells (TCR-T; T-Plex) expressing a high-affinity TCR specific for MAGE-A1 peptide presented by HLA-A*01:01; targets peptide–HLA on tumor cells to induce TCR/CD3-mediated cytotoxic killing after lymphodepletion.
Autologous T cells are gene-modified to express a high-affinity TCR specific for the MAGE-A1 peptide presented by HLA-A*01:01. After lymphodepletion, these TCR-T cells recognize the peptide–HLA complex on tumor cells, activate TCR/CD3 signaling, and mediate targeted cytotoxic killing.
NO
INDIRECT
Engineered TCR-T cells kill only cells presenting the MAGE-A1 peptide in the HLA-A*01:01 complex; HLA-A*01:01 alone is not sufficient. When the peptide–HLA complex is present, TCR/CD3 signaling triggers perforin/granzyme-mediated cytolysis.
Autologous, gene-modified TCR-engineered T cells (TCR-T; T-Plex) expressing a high-affinity TCR specific for MAGE-C2 peptide presented by HLA-B*07:02; recognizes peptide–HLA on tumor cells to trigger TCR/CD3 signaling and cytotoxicity following lymphodepletion.
Autologous T cells are gene-modified to express a high-affinity TCR specific for the MAGE-C2 peptide presented by HLA-B*07:02. Binding to the peptide–HLA complex on tumor cells triggers TCR/CD3 signaling, activating the T cells to mediate cytokine release and targeted cytotoxic killing of antigen-positive tumor cells following lymphodepletion.
YES
DIRECT
Engineered TCR-T cells bind the MAGE-C2 peptide presented by HLA-B*07:02 on tumor cells, triggering TCR/CD3 activation and perforin/granzyme (and Fas/FasL)–mediated killing of antigen-positive cells.
Autologous, gene-modified TCR-engineered T cells (TCR-T; T-Plex) expressing a high-affinity TCR specific for MAGE-C2 peptide presented by HLA-B*07:02; recognizes peptide–HLA on tumor cells to trigger TCR/CD3 signaling and cytotoxicity following lymphodepletion.
Autologous T cells are gene-modified to express a high-affinity TCR specific for the MAGE-C2 peptide presented by HLA-B*07:02. Binding to the peptide–HLA complex on tumor cells triggers TCR/CD3 signaling, activating the T cells to mediate cytokine release and targeted cytotoxic killing of antigen-positive tumor cells following lymphodepletion.
NO
INDIRECT
Engineered TCR-T cells recognize the MAGE-C2 peptide presented by HLA-B*07:02, triggering TCR/CD3 activation and perforin/granzyme-mediated killing. HLA-B*07:02 expression alone is not sufficient for killing.
Autologous, gene-modified TCR-engineered T cells (TCR-T; T-Plex) expressing a high-affinity TCR specific for MAGE-A4 peptide presented by HLA-A*02:01; mediates recognition of peptide–HLA on tumor cells and TCR/CD3-driven cytotoxic killing after lymphodepletion.
Autologous T cells are gene-modified to express a high-affinity TCR specific for the MAGE-A4 peptide presented by HLA-A*02:01. Upon recognizing the peptide–HLA complex on tumor cells, the introduced TCR triggers TCR/CD3 signaling, leading to T-cell activation and cytotoxic killing of target cells. Activity is HLA-A*02:01–restricted and antigen-dependent, and therapy is administered after lymphodepletion to enhance engraftment and function.
YES
DIRECT
Engineered TCR-T cells recognize the MAGE-A4 peptide presented on HLA-A*02:01, activate via TCR/CD3, and kill target cells via perforin/granzyme release (and death-receptor pathways).
Autologous, gene-modified TCR-engineered T cells (TCR-T; T-Plex) expressing a high-affinity TCR specific for MAGE-A4 peptide presented by HLA-A*02:01; mediates recognition of peptide–HLA on tumor cells and TCR/CD3-driven cytotoxic killing after lymphodepletion.
Autologous T cells are gene-modified to express a high-affinity TCR specific for the MAGE-A4 peptide presented by HLA-A*02:01. Upon recognizing the peptide–HLA complex on tumor cells, the introduced TCR triggers TCR/CD3 signaling, leading to T-cell activation and cytotoxic killing of target cells. Activity is HLA-A*02:01–restricted and antigen-dependent, and therapy is administered after lymphodepletion to enhance engraftment and function.
NO
INDIRECT
HLA-A*02:01 alone is not targeted. Killing occurs only when tumor cells present the MAGE-A4 peptide on HLA-A*02:01, which is recognized by the engineered TCR, triggering T-cell cytotoxicity (perforin/granzyme).